Share this postThe Drug Development LetterSpecial post-ESMO 2024 edition !Copy linkFacebookEmailNotesMorePlayback speed×Share postShare post at current timeShare from 0:000:00/0:00Transcript13Share this postThe Drug Development LetterSpecial post-ESMO 2024 edition !Copy linkFacebookEmailNotesMore11Special post-ESMO 2024 edition !Timothee Olivier and I discuss the top ESMO 2024 abstracts!Vinay Prasad and Timothée OlivierNov 03, 202413Share this postThe Drug Development LetterSpecial post-ESMO 2024 edition !Copy linkFacebookEmailNotesMore11ShareTranscriptThe Drug Development Letter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.SubscribeDiscussion about this videoCommentsRestacksShare this postThe Drug Development LetterSpecial post-ESMO 2024 edition !Copy linkFacebookEmailNotesMoreThe Drug Development LetterSubscribeAuthorsVinay PrasadTimothée OlivierRecent PostsCDK4/6 Inhibitors and Novel Adjuvant Therapies: Using Statistics to Inform Shared Decision-Making Mar 4 • Timothée OlivierThe CABINET studyFeb 21 • Vinay PrasadRANDOMIZED versus REAL-WORLD EVIDENCE ON THE EFFICACY AND TOXICITY OF CHECKPOINT INHIBITORS.Dec 15, 2024 • Timothée OlivierSpecial ESMO 2024 edition !Sep 14, 2024 • Vinay Prasad and Timothée OlivierDriver mutation lung cancerSep 9, 2024 • Vinay PrasadSpecial post-ASCO 2024 edition !Jun 9, 2024 • Vinay Prasad and Timothée OlivierASCO pre-game showMay 30, 2024 • Vinay Prasad
Share this post